Humana (HUM) Projected to Post Earnings on Wednesday

Humana (NYSE:HUM) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, April 30th. Analysts expect Humana to post earnings of $9.95 per share and revenue of $32.00 billion for the quarter. Humana has set its FY 2025 guidance at 16.250-16.250 EPS.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $13 EPS for the next fiscal year.

Humana Stock Performance

HUM opened at $258.87 on Wednesday. The business has a fifty day simple moving average of $265.74 and a 200-day simple moving average of $270.19. The firm has a market cap of $31.24 billion, a PE ratio of 26.02, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.37%. Humana’s dividend payout ratio is currently 35.58%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on HUM shares. Piper Sandler upped their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Robert W. Baird raised their target price on Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 15th. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Morgan Stanley reduced their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, Truist Financial upped their price objective on shares of Humana from $290.00 to $325.00 and gave the company a “hold” rating in a research note on Friday, April 11th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average target price of $284.90.

Institutional Investors Weigh In On Humana

A hedge fund recently bought a new stake in Humana stock. Revolve Wealth Partners LLC acquired a new position in shares of Humana Inc. (NYSE:HUM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 798 shares of the insurance provider’s stock, valued at approximately $202,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.